Fig. 6.
Significantly shorter EFS (A) and OS (B) in 23 patients (10%) with β2M > 4 and unfavorable karyotypes (▵ 11/13) compared with the 206 remaining patients (161 with β2M ≤ 4 mg/L and 45 with β2M > 4 mg/L but absence of ▵ 11/13).
Significantly shorter EFS (A) and OS (B) in 23 patients (10%) with β2M > 4 and unfavorable karyotypes (▵ 11/13) compared with the 206 remaining patients (161 with β2M ≤ 4 mg/L and 45 with β2M > 4 mg/L but absence of ▵ 11/13).
